Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO® ...

Good evening and welcome to Doctors on Call back on our we're back on our 45th season at this time. I'm Dr. Ray Christensen, ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announced that it will host a Capital Markets Day in Melbourne, Australia, on Wednesday, November 4, 2026, from 9:00 a.m. to 12:30 ...

Fear of accusations of infidelity, the stigma surrounding HIV and concerns about causing conflict in a relationship might ...

"Starting the HIV PrEP Conversation in Primary Care and Pharmacy" takes up the question of how clinicians and pharmacists can start the PrEP conversation, and who should be having it.

For men diagnosed with localized prostate cancer, radiation treatment has long meant a difficult trade-off: either endure ...

DSS Takara Bio supports prostate cancer research through molecular profiling, transcriptomics and sequencing technologies for ...

FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting. The designation recognizes the ...

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging. Melbourne (Australia) and Indianapolis, IN (United States) \| September 30, 2026. FDA Fast T ...

Medicus Pharma submitted a seamless Phase 2b/3 protocol to the FDA for Teverelix, targeting advanced prostate cancer with ...